High-dose chemotherapy and autologous stem cell transplant leads to significant immunodeficiency. 1 The standard of care is vaccination against infectious agents beginning 3-12 months after transplant. 2 To improve early post-transplant immunity, preor post-chemotherapy vaccination strategies were designed to capitalize on immune cell homeostatic proliferation occurring after chemotherapy-induced lymphopenia. 3, 4 These strategies induce antibody and T-cell responses against infectious antigens and tumor-associated antigens, 4 -6 yet responses are incremental over controls unless additional cellular manipulations, such as ex vivo polyclonal activation of T-cells or dendritic cell-tumor fusions are performed. 7, 8 Using a murine model, Brody et al. demonstrated that vaccination before hematopoietic cell collection elicits strong post-transplant CD4+ and CD8+ responses which were potentiated by additional vaccination immediately post transplant, and they named this procedure 'immunotransplant'. 9 Pneumococcal vaccination before stem cell collection was previously tested revealing antibody responses, however early posttransplant vaccination was not performed and T-cell responses were not demonstrated. 4 None of these human trials coupled immunization just before standard G-CSF primed unfractionated hematopoietic cell collection with immunization again early post transplant, during the period of homeostatic proliferation.
We hypothesized that immune responses could be generated by vaccination and immunotransplant without ex vivo T-cell expansion. To test this, we conducted a feasibility and biological activity study of Prevnar-13 (PCV-13), a pneumococcal 13-valent conjugate (diphtheria CRM197 protein) vaccination, administered in a novel schedule in conjunction with standard high-dose melphalan chemotherapy (200 mg/m 2 ) and autologous hematopoietic cell transplant for adult patients with multiple myeloma. PCV-13 was administered before G-CSF mobilization and hematopoietic cell collection and again during the lymphopenic period, 7-21 days after transplant. All patients signed informed consent to this Institutional Review Board approved study registered on ClinicalTrials.gov (NCT01852591). Patients were scheduled to receive up to three IM injections of 0.5 mL of PCV-13. Each vaccine contains serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to a nontoxic variant of diphtheria toxin (CRM197). The three vaccine administrations were scheduled as follows: (1) between 3 and 30 days before the first day of standard G-CSF administration for hematopoietic cell mobilization; (2) between day +7 and +10 after autologous hematopoietic cell infusion (that is, transplant); and (3) between day +21 and +24 after transplant. Vaccine was deferred for platelets o 50 000 cells/microL, fever, or systemic inflammatory response syndrome. Adverse events not expected with standard autologous transplant were graded using CTCAE v4.03 following each vaccination to day +90 and assigned by the treating physician as possible, probable or unlikely related to vaccination.
Biological endpoints of this study included antibody responses against pneumococcal serotypes and T-cell responses against CRM197.
Patient sera were collected pre-vaccine and day +90 post transplant and sent to ARUP laboratories (Salt Lake City, UT, USA) for evaluation of antibodies against 11 pneumococcal serotypes included in PCV-13 (1,3,4,5,6B,7F,9V,14,18C,19and 23) and three nonvaccine serotypes (8, 9N and 12F) . In cases where ARUP reported that the absolute IgG value was greater than their maximum calculated titer, the maximum value was used for graphing and statistical purposes. Peripheral blood mononuclear cells were collected pre-vaccine, day+30, and day+90 post transplant and flow cytometry was performed concurrently for all time points for each patient. Cells were labeled with CellTrace Violet (CTV; Invitrogen, Waltham, MA, USA) and seeded into a 96-well flat bottom plate (1 × 10 5 cells/well) in X-VIVO media containing 10% human AB serum (SeraCare, Milford, MA, USA). CRM197 (10 μg/mL in DMSO) or DMSO vehicle only was added to each well. CTV allows for flow differentiation of divided (CTV-) and nondivided (CTV+) populations. Cells were cultured for 5 days then collected for analysis. Staining for cell surface (CD3, CD4, CD8, and CD107a) and intracellular markers (interferon gamma (IFN-gamma)) was performed per manufacturers protocols. Live/ Dead fixable yellow stain (Life Technologies, Carlsbad, CA, USA, L34959) was used to stain dead cells. Cell surface staining antibodies (BD Biosciences, East Rutherford, NJ, USA) used were CD3-APC, CD4-PerCPCy5.5, CD8-FITC, CD107a-PECy7 and IFN-gamma-PE.
Eight patients consented to the trial, two of whom withdrew consent before transplant and immune evaluation. Six patients were evaluable for safety and biological end points. Two subjects received the full vaccination series. Three patients received two vaccines (pre-transplant and day+21), as day+7 vaccine was held due to thrombocytopenia. One patient received neither day +7 nor +21 vaccines due to thrombocytopenia. The vaccines were well tolerated and only expected side effects were observed. 10 No grade 3-5 adverse events attributable to the vaccine were observed. Of grade 1 and 2 adverse events attributable to vaccination, localized injection site reactions were most frequent: four patients reported pain, swelling or tenderness. Grade 1 systemic adverse events of headache (n = 2), nausea (n = 1) and vomiting (n = 1) were encountered. One subject developed a grade 2 rash on day +8 post transplant possibly vaccine related, although skin biopsy was inconclusive. These results support our hypothesis that administration of PCV-13 pre-mobilization and early post transplant is safe.
To determine the effectiveness of this vaccination schedule at eliciting antibody responses after transplant, we first evaluated the increase in pneumococcal serotypes for each patient. All patients who received pre-and post-transplant vaccinations had a significantly greater increase in vaccine-specific pneumococcal serotype IgG (day+90/pre-vaccine) as compared with the change in pneumococcal serotype IgG not included in the vaccine (Figure 1a) . One patient, who only received pre-transplant vaccination due to posttransplant thrombocytopenia, did not have an increase in vaccine serotype IgGs compared with nonvaccine serotypes (pt.05, Figure 1a) . Of the 11 vaccine-specific serotype IgG levels tested, six were significantly increased from pre-vaccine to day+90 after transplant. IgG levels were equivalent for 3 of 3 nonvaccine serotypes (Figure 1b) . Grouping serotype responses together demonstrated a significant increase in the absolute IgG levels of vaccine-specific serotypes following vaccination and transplant (Geometric mean IgG = 0.45(95% CI = 0.33-0.66) pre-vaccine to 4.12(95% CI = 2.7-6.2) at day+90 posttransplant (Po 0.001)). Nonvaccine serotype IgG levels were equivalent pre-vaccine to day+90 (Figure 1c ). All vaccinated patients had a positive response as defined by pre-study criteria. Taking the entire set of evaluable patients into account, six of the eleven vaccine-specific serotype IgG levels were significantly increased at day +90 after transplant, which is notable given the small series of patients. In two patients the nonvaccine serotype, 9N, was increased suggesting cross reactivity with vaccine serotype 9V. 11 Antin et al. previously used the similar PCV-7 conjugate vaccine prior to autologous bone marrow or peripheral blood hematopoietic stem cell collection. In contrast to our study, that trial did not include post-transplant vaccination until day+90. Seven serotypes are contained in both PCV-13 and PCV-7 (4, 6B, 9V, 14C, 18C, 19F and 23F). The geometric mean of those IgG levels at day +90, in our patients, were significantly higher compared with that of the published data (not shown, P = 0.02 paired t-test). 4 Taken together this suggest that post-transplant vaccination during lymphopenia boosts immune responses beyond that achieved with vaccine given immediately before standard stem cell collection.
We next evaluated the effectiveness of the vaccine at generation of post-transplant T-cell responses by flow cytometry. Vaccine administered in this schedule elicited an increase in CD4+ cells that divided and expressed intracellular IFN-gamma in response to CRM197. Figure 2a shows the flow plot of the patient with the best CD4+ response against CRM197 at day +30 after transplant. There was a significant increase in patients' percent of CD4+ cells that divided (CTV-) and expressed intracellular IFN-gamma at day+30 and day+90 after transplant as compared with pre-vaccine (Figure 2b) . Similarly, increased CD8+ responses against CRM197 were observed. Figure 2c shows the flow plot of the best CD8+ response against CRM197 at day +30 after transplant. Overall, the vaccine elicited an increase in CD8+ cells that divided (CTV-) and expressed intracellular IFN-gamma in response to CRM197 (Figure 2d ). Figure 2e shows the best CD8 +CD107a+ response to CRM197. Vaccine also increased the percent of CD8+ cells that express CD107a at day+90 after transplant in response to CRM197 (Figure 2f ). These results demonstrate that this unique vaccination strategy safely elicits CD4+ helper and CD8+ cytotoxic responses, results not previously demonstrated without the use of ex vivo cellular manipulations. 4, 7 An immunotherapy strategy building upon autologous transplant that does not require ex vivo T-cell manipulation could provide advantages, 12 such as the maintenance of the T-central memory state linked to long-lasting anti-tumor immunity. 13 In conclusion, this proof-of-principle trial shows that both humoral and cellular immune responses can be potentiated via vaccination before G-CSF mobilized hematopoietic cell collection and again early after autologous transplantation. All patients that received both pre-collection and day +21 post-transplant vaccinations demonstrated significant immune responses. Not all patients were able to get the day+7 posttransplant IM vaccination due to thrombocytopenia. Before widespread adoption additional testing is warranted to confirm protective antibody and T-cell responses in a larger cohort of patients. We believe these results justify using this schedule (pre G-CSF mobilization and on day+21 post transplant) for anti-tumor-associated antigen vaccination strategies.
